

The Neo-ACT trial

Newsletter, December 2023

Jana de Boniface, Cecilia Ringborg, Renske Altena, Yvonne Wengström and Marie Westman




The Neo-ACT team wishes everyone a very Merry Christmas and Happy New Year!



Inclusion is up and running in Sweden and Finland

Neo-ACT has randomised 72 participants so far! An extra congratulation to Skaraborg, Södersjukhuset, Västerås, och Umeå that have randomised their first participant since the previous newsletter.



A poster of Neo-ACT trial was recently presented at the San Antonio Breast Cancer Symposium by Jana de Boniface (scan the QR code below for a view).



International expansion


The expansion of the trial to further international sites is ongoing. German sites are planned to join during spring 2024 via EUBREAST (European Breast Cancer Research Association of Surgical Trialists). Hopefully, we can soon also welcome additional English-speaking countries (Australia, England, Scotland, Canada). Additional countries and languages may follow in due course.

New funding

Radiumhemmets Research Funds are now also supporting the trial.

Patient reimbursement increased

The site reimbursement per patient will increase to 600 Euro / 450 GBP from January 2024.



Homepage

For any purposes and needs, please visit our trial homepage.

<https://ki.se/en/mmk/the-neo-act-trial>

Contact:

Trial management

marie.westman@cytel.com



Kind regards,
The Neo-ACT Team